Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy

Anne Mette Lund Würtz; Anne Tjønneland; Jane Hvarregaard Christensen; Lars Ove Dragsted; Julie Aarestrup; Cecilie Kyrø; Kim Overvad; Anja Olsen

doi:10.1007/s10552-012-0050-7

Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy

Anne Mette Lund Würtz, Anne Tjønneland, Jane Hvarregaard Christensen, Lars Ove Dragsted, Julie Aarestrup, Cecilie Kyrø, Kim Overvad, Anja Olsen

9 Citations (Scopus)

Abstract

Objective Levels of endogenous estrogen and SHBG are associated with risk of breast cancer among women who have never used hormone replacement therapy (HRT). We investigated these associations in both never and baseline users of HRT. Methods A nested case-control study was conducted within the prospective Danish population-based 'Diet, Cancer, and Health' cohort. During follow-up, 348 eligible cases were identified among 20,861 postmenopausal women and matched to 348 controls. Baseline serum samples were analyzed for estradiol, bioavailable estradiol, estrone, estrone sulfate, and SHBG. Conditional logistic regression yielded incidence rate ratios and 95 % confidence intervals for exposures analyzed continuously and categorically in models adjusted for potential confounders. Results Modest direct associations were identified between estrogen levels and breast cancer incidence among both never and baseline HRT users. Estrone and estrone sulfate were more consistently associated among both groups than estradiol. No association was found with SHBG. Conclusion Despite different hormonal profiles, higher serum estrogen levels were associated with a higher risk of breast cancer among both never and baseline HRT users. More studies are needed to support the findings for HRT users and to further investigate estrogen levels in relation to estrogen receptor-specific breast cancer and other histological and molecular subtypes.

Original language	English
Journal	Cancer Causes & Control
Volume	23
Issue number	10
Pages (from-to)	1711-1720
Number of pages	10
ISSN	0957-5243
DOIs	https://doi.org/10.1007/s10552-012-0050-7
Publication status	Published - Oct 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10552-012-0050-7

Cite this

@article{1ee6de1e008644f18bb5171c96ad3f9f,

title = "Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy",

abstract = "Objective Levels of endogenous estrogen and SHBG are associated with risk of breast cancer among women who have never used hormone replacement therapy (HRT). We investigated these associations in both never and baseline users of HRT. Methods A nested case-control study was conducted within the prospective Danish population-based 'Diet, Cancer, and Health' cohort. During follow-up, 348 eligible cases were identified among 20,861 postmenopausal women and matched to 348 controls. Baseline serum samples were analyzed for estradiol, bioavailable estradiol, estrone, estrone sulfate, and SHBG. Conditional logistic regression yielded incidence rate ratios and 95 % confidence intervals for exposures analyzed continuously and categorically in models adjusted for potential confounders. Results Modest direct associations were identified between estrogen levels and breast cancer incidence among both never and baseline HRT users. Estrone and estrone sulfate were more consistently associated among both groups than estradiol. No association was found with SHBG. Conclusion Despite different hormonal profiles, higher serum estrogen levels were associated with a higher risk of breast cancer among both never and baseline HRT users. More studies are needed to support the findings for HRT users and to further investigate estrogen levels in relation to estrogen receptor-specific breast cancer and other histological and molecular subtypes.",

author = "W{\"u}rtz, {Anne Mette Lund} and Anne Tj{\o}nneland and Christensen, {Jane Hvarregaard} and Dragsted, {Lars Ove} and Julie Aarestrup and Cecilie Kyr{\o} and Kim Overvad and Anja Olsen",

note = "IHE 2012 071",

year = "2012",

month = oct,

doi = "10.1007/s10552-012-0050-7",

language = "English",

volume = "23",

pages = "1711--1720",

journal = "Cancer Causes & Control",

issn = "0957-5243",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy

AU - Würtz, Anne Mette Lund

AU - Tjønneland, Anne

AU - Christensen, Jane Hvarregaard

AU - Dragsted, Lars Ove

AU - Aarestrup, Julie

AU - Kyrø, Cecilie

AU - Overvad, Kim

AU - Olsen, Anja

N1 - IHE 2012 071

PY - 2012/10

Y1 - 2012/10

N2 - Objective Levels of endogenous estrogen and SHBG are associated with risk of breast cancer among women who have never used hormone replacement therapy (HRT). We investigated these associations in both never and baseline users of HRT. Methods A nested case-control study was conducted within the prospective Danish population-based 'Diet, Cancer, and Health' cohort. During follow-up, 348 eligible cases were identified among 20,861 postmenopausal women and matched to 348 controls. Baseline serum samples were analyzed for estradiol, bioavailable estradiol, estrone, estrone sulfate, and SHBG. Conditional logistic regression yielded incidence rate ratios and 95 % confidence intervals for exposures analyzed continuously and categorically in models adjusted for potential confounders. Results Modest direct associations were identified between estrogen levels and breast cancer incidence among both never and baseline HRT users. Estrone and estrone sulfate were more consistently associated among both groups than estradiol. No association was found with SHBG. Conclusion Despite different hormonal profiles, higher serum estrogen levels were associated with a higher risk of breast cancer among both never and baseline HRT users. More studies are needed to support the findings for HRT users and to further investigate estrogen levels in relation to estrogen receptor-specific breast cancer and other histological and molecular subtypes.

AB - Objective Levels of endogenous estrogen and SHBG are associated with risk of breast cancer among women who have never used hormone replacement therapy (HRT). We investigated these associations in both never and baseline users of HRT. Methods A nested case-control study was conducted within the prospective Danish population-based 'Diet, Cancer, and Health' cohort. During follow-up, 348 eligible cases were identified among 20,861 postmenopausal women and matched to 348 controls. Baseline serum samples were analyzed for estradiol, bioavailable estradiol, estrone, estrone sulfate, and SHBG. Conditional logistic regression yielded incidence rate ratios and 95 % confidence intervals for exposures analyzed continuously and categorically in models adjusted for potential confounders. Results Modest direct associations were identified between estrogen levels and breast cancer incidence among both never and baseline HRT users. Estrone and estrone sulfate were more consistently associated among both groups than estradiol. No association was found with SHBG. Conclusion Despite different hormonal profiles, higher serum estrogen levels were associated with a higher risk of breast cancer among both never and baseline HRT users. More studies are needed to support the findings for HRT users and to further investigate estrogen levels in relation to estrogen receptor-specific breast cancer and other histological and molecular subtypes.

U2 - 10.1007/s10552-012-0050-7

DO - 10.1007/s10552-012-0050-7

M3 - Journal article

C2 - 22926300

SN - 0957-5243

VL - 23

SP - 1711

EP - 1720

JO - Cancer Causes & Control

JF - Cancer Causes & Control

IS - 10

ER -

Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this